Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys and Ribavirin in Chronic Hepatitis C Genotype 2/3
NCT01258101Phase 4Completed
- Sponsor
- Roche
- Start
- May 2003
- Primary completion
- Jul 2008
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C (HCV) (4 arms), sponsored by Roche. Primary endpoints: Sustained Virologic Response Rate and Hepatitis C Virus-RNA at Week 48. Started May 2003; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01258101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01258101.